Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Tepotinib Pharmacokinetics in Healthy Participants
NCT05203822Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity, Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration and 1 more. Started Jan 2022; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05203822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203822.